The roles are blurring: firms like A16Z don't just exit at IPO. They may become the largest buyer *in* the IPO, as they did with Samsara, if they believe the public market is undervaluing the company's long-term prospects.

Related Insights

The traditional IPO exit is being replaced by a perpetual secondary market for elite private companies. This new paradigm provides liquidity for investors and employees without the high costs and regulatory burdens of going public. This shift fundamentally alters the venture capital lifecycle, enabling longer private holding periods.

When a credible, external VC leads a follow-on round at what seems like a high price, it provides a strong signal of validation. This should prompt existing investors to overcome their anchoring bias and increase their own investment.

Top-tier venture capital firms are developing internal platforms with such demonstrable results and strong reputations that founders choose them over competitors offering higher valuations, seeking access to their unique support ecosystem.

For late-stage startups, securing a pre-IPO round led by a premier public market investor like Fidelity is a strategic move. It provides more than capital; it offers a crucial stamp of approval that builds significant confidence and credibility with Wall Street ahead of an IPO.

Firms like Sequoia investing in direct competitors (OpenAI and Anthropic) shows that late-stage venture has evolved. When taking small, non-board seat stakes for hundreds of millions, firms act like public market funds, buying a portfolio of category leaders without the information access that would create a true conflict.

Contrary to the popular VC idea that IPO pops are 'free money' left on the table, they actually serve as a crucial risk premium for public market investors. Down-rounds like Navan's prove that buyers need the upside from successful IPOs to compensate for the very real risk of losing money on others.

The venture capital paradigm has inverted. Historically, private companies traded at an "illiquidity discount" to their public counterparts. Now, for elite companies, there is an "access premium" where investors pay more for private shares due to scarcity and hype. This makes staying private longer more attractive.

The abundance of private capital means the most successful companies no longer need to go public for growth funding. This disrupts the traditional VC model, where IPOs are a primary exit path, forcing firms to re-evaluate how and when they achieve liquidity for their limited partners, even for their best assets.

With trillion-dollar IPOs likely, the old model where early VCs win by having later-stage VCs "mark up" their deals is obsolete. The new math dictates that significant ownership in a category winner is immensely valuable at any stage, fundamentally changing investment strategy for the entire industry.

A successful biotech IPO isn't about attracting the public; it's about securing commitments from crossover investors beforehand. These investors must "bring their own beer to the party" by participating in the IPO. Their presence validates the company, stabilizes the offering, and is essential for attracting generalist funds later.